微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 51.21% | -2.47% | -7.49% | 67/158 | 32.3% | 华特达因 | 85.78% | 行业排名> |
| 2024-12-31 | 55.36% | -7.75% | 3.55% | 67/158 | 51.8% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 53.46% | -5.32% | -5.57% | 70/158 | 22.73% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 56.61% | 3.15% | 7.81% | 64/158 | 33.18% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 52.51% | 2.83% | -12.5% | 71/158 | 51.56% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 60.01% | 18.13% | 6.28% | 53/158 | 51.38% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 56.46% | 17.2% | 2.88% | 65/158 | 32.56% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 54.88% | 21.28% | 7.48% | 68/158 | 38.45% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 51.06% | 16.46% | 0.52% | 74/158 | 52.78% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 50.8% | 0.67% | 5.44% | 85/158 | 53.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 48.17% | 5.33% | 6.46% | 83/158 | 6.2% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 45.25% | 8.97% | 3.21% | 89/158 | 21.37% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 43.84% | 14.15% | -13.1% | 86/158 | 54.28% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 50.46% | -1.65% | 10.33% | 83/158 | 55.1% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 45.73% | -7.7% | 10.14% | 80/158 | 46.78% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 41.53% | -14.31% | 8.11% | 95/158 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 38.41% | -13.76% | -25.13% | 89/158 | 53.99% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 51.3% | 6.28% | 3.54% | 78/158 | -145.9% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 49.55% | 5.14% | 2.25% | 69/158 | 56.36% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 48.46% | 2.81% | 8.8% | 76/158 | 54.11% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 44.54% | -5.77% | -7.73% | 74/158 | 55.23% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 48.27% | 8.09% | 2.43% | 81/158 | -1222.98% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 47.13% | 3.01% | -0.02% | 65/158 | 55.21% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 47.14% | 8.09% | -0.28% | 68/158 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 47.27% | 8.94% | 5.84% | 64/158 | 51.05% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 44.66% | 7.4% | -2.38% | 82/158 | -208.09% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 45.75% | 10.91% | 4.91% | 62/158 | 53.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 43.61% | 5.53% | 0.5% | 67/158 | 53.39% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 43.39% | 14.6% | 4.35% | 64/158 | 53.9% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 41.58% | 0.11% | 0.81% | 76/158 | 52.32% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 41.25% | 4.22% | -0.18% | 57/158 | 49% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 41.32% | 6.24% | 9.14% | 58/158 | 47.74% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 37.86% | -4.83% | -8.85% | 55/158 | 46.55% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 41.54% | -16.71% | 4.96% | 67/158 | 48.19% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 39.58% | -25.44% | 1.75% | 47/158 | 45.76% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 38.9% | -27.66% | -2.23% | 52/158 | 45.89% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 39.78% | -10.33% | -20.23% | 41/158 | 43.5% | 微芯生物 | 97.46% | 行业排名> |
| 2015-12-31 | 49.87% | -4.14% | -6.04% | 43/158 | 45.97% | 贝达药业 | 97.01% | 行业排名> |
| 2015-09-30 | 53.08% | 2.89% | -1.28% | 24/158 | 44.69% | 贝达药业 | 97.02% | 行业排名> |
| 2015-06-30 | 53.77% | 7.43% | 21.18% | 27/158 | 45% | 舒泰神 | 94.38% | 行业排名> |
| 2015-03-31 | 44.37% | -4.7% | -14.72% | 35/158 | 43.46% | 贝达药业 | 96.95% | 行业排名> |